Teng, Kai Wen
Tsai, Steven T.
Hattori, Takamitsu
Fedele, Carmine
Koide, Akiko
Yang, Chao
Hou, Xuben
Zhang, Yingkai http://orcid.org/0000-0002-4984-3354
Neel, Benjamin G.
O’Bryan, John P.
Koide, Shohei http://orcid.org/0000-0001-5473-4358
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (F32 CA225131, R01 CA194864, R01 CA212608)
American Cancer Society (PF-18-180-01-TBE)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Article History
Received: 23 October 2020
Accepted: 7 April 2021
First Online: 11 May 2021
Competing interests
: K.W.T., A.K., T.H., and S.K. are listed as inventors on a patent application on RAS-targeting monobodies filed by New York University (Application No. 63/121,903). A.K. and S.K. are listed as inventors on issued and pending patents on the monobody technology filed by The University of Chicago (US Patent 9512199 B2 and related pending applications). B.G.N. is a co-founder, chair of the Scientific Advisory Board (SAB), and holds equity in Navire Pharmaceuticals; a co-founder and SAB member and holds equity in and receives consulting fees from Northern Biologics; an SAB member and holds equity in and receives consulting fees from Arvinas; an SAB member and holds equity in Recursion Pharma; a co-founder and holds equity in and receives consulting fees from Jengu Therapeutics; serves as an expert witness for Johnson and Johnson; his spouse owns shares in Amgen. S.K. is an SAB member and holds equity in and receives consulting fees from Black Diamond Therapeutics; receives research funding from Puretech Health and Argenx BVBA. The other authors declare no competing interests.